Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 4, 2004, Pages 343-353

  Mortenson, Melinda M ^a   Schlieman, Michael G ^a   Virudachalam, Subbulakshmi ^a   Bold, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Bortezomib; Lung cancer; p21waf1 cip1; Proteasome inhibitor

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; BORTEZOMIB; CARBOPLATIN; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; GEMCITABINE; GEMFIBROZIL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; STAINING; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEASE INHIBITORS; PYRAZINES; TUMOR CELLS, CULTURED;

EID: 4644328614     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0811-4     Document Type: Article

References (56)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26
2. Spiro SG, Porter JC (2002) Lung cancer-where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166:1166-1196
3. Cortes-Funes H (2003) New treatment approaches for lung cancer and impact on survival. Semin Oncol 29:26-29
4. Crino L, Cappuzzo F (2002) Present and future treatment of advanced non-small cell lung cancer. Semin Oncol 29:9-16
5. Adams J (2002) Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14:628-634
6. Cusack JC (2003) Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29 [Suppl 1]:21-31
7. Garber K (2002) Cancer research. Taking garbage in, tossing cancer out? Science 295:612-613
8. Naujokat C, Hoffman S (2002) Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 82:965-980
9. Adams J (2003) The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29 [Suppl 1]:3-9
10. Gregory MA, Hann SR (2000) c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 20:2423-2435
11. Acquaviva C, Bossis G, Ferrara P, Brockly F, Jariel-Encontre I, Piechaczyk M (2002) Multiple degradation pathways for Fos family proteins. Ann N Y Acad Sci 973:426-434
12. Jariel-Encontre I, Salvat C, Steff AM, Pariat M, Acquaviva C, Furstoss O, Piechaczyk M (1997) Complex mechanisms for c-fos and c-jun degradation. Mol Biol Rep 24:51-56
13. Roff M, Thompson J, Rodriguez MS, Jacque JM, Baleux F, Arenzana-Seisdedos F, Hay RT (1996) Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem 271:7844-7850
14. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, Zhao M, Miyauch M, Nikai H (2000) p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 6:916-923
15. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS (1996) Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 227:564-569
16. Frankel A, Man S, Elliott P, Adams J, Kerbel RS (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728
17. Paramore A, Frantz S (2002) Bortezomib. Nat Rev Drug Discov 2:611-612
18. Adams J (2002) Development of the proteasome inhibitor PS-341. Oncologist 7:9-16
19. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622
20. Twombly R (2003) First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 95:845
21. Richardson PG, Hideshima T, Anderson KC (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10:361-369
22. Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29 [Suppl 1]:41-48
23. Ling Y, Liebes L, Jiang J, Holland JF, Elliot PJ, Adams J, Muggia FM, Perez-Soler R (2003) Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer lines. Clin Cancer Res 9:1145-1154
24. An WG, Hwang SG, Trepel JB, Blagosklonny MV (2000) Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14:1276-1283
25. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS (1996) Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 227:564-569
26. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR (2003) Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 41:589-596
27. Hayashi H, Miyamoto H, Ito T, Kameda Y, Nakamura N, Kubota Y, Kitamura H (1997) Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Am J Pathol 151:461-470
28. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H (2002) Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 20:3865-3871
29. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, Kikui M, Ohno A, Fukuoka M, Kawase I (1997) p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 3:1831-1835
30. Drexler HC (2003) The role of p27Kip1 in proteasome inhibitor induced apoptosis. Cell Cycle 2:438-441
31. Imai J, Yashiroda H, Maruya M, Yahara I, Tanaka K (2003) Proteasomes and molecular chaperones: cellular machinery responsible for folding and destruction of unfolded proteins. Cell Cycle 2:585-590
32. Harper P (2003) Update on gemcitabine/carboplatin combination in patients with advanced non-small cell lung cancer. Semin Oncol 30:2-12
33. Zatloukal P, Petruzelka L (2003) Gemcitabine/carboplatin combination in advanced non-small cell lung cancer. Lung Cancer 38 [Suppl 2]:S33-S36
34. Domine M, Casado V, Estevez LG, Leon A, Martin JI, Castillo M, Rubio G, Lobo F (2001) Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer. Semin Oncol 28 [3 Suppl 10]:4-9
35. Denizot F, Lang R (1986) Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 22:271-277
36. Kapuscinski J (1995) DAPI: a DNA-specific fluorescent probe. Biotech Histochem 70:220-233
37. Grenman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR, Carey TE (1989) Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44:131-136
38. Fahy BN, Schlieman M, Virudachalam S, Bold RJ (2003) AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br J Cancer 89:391-397
39. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ (2002) Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243-1253
40. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliot PJ, Adams J, Gallery MP (2001) 26S Proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biol 82:110-122
41. Bold RJ, Virudachalam S, McConkey DJ (2001) Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 99:1-7
42. Cusack JC, Liu R, Houston M, Abendroth K, Elliot PJ, Adams J, Baldwin AS (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kB inhibition. Cancer Res 61:3535-3540
43. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102:303-310
44. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D (2001) In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37:69-82
45. Schreiber M, Muller WJ, Singh G, Graham FL (1999) Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18:1663-1676
46. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35:796-807
47. Coleman SC, Stewart ZA, Day TA, Netterville JL, Burkey BB, Pietenpol JA (2002) Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Arch Otolaryngol Head Neck Surg 128:167-176
48. Perez EA, Buckwalter CA (1998) Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines. Cancer Chemother Pharmacol 41:448-452
49. Zoli W, Ricotti L, Barzanti F, Dal Susino M, Frassineti GL, Milandri C, Casadei-Giunchi D, Amadori D (1999) Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80:413-416
50. Zeng S, Chen YZ, Fu L, Johnson KR, Fan W (2000) In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Cancer Res 6:3766-3773
51. Kano Y, Akutsu M, Tsunoda S, Mori K, Suzuki K, Adachi KI (1998) In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 42:91-98
52. Blagosklonny MV (2000) Cell death beyond apoptosis. Leukemia 14:1502-1508
53. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Andersen KC (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-4086
54. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H (2003) Role of NF-kappaB and Akt/ PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22:3243-3251
55. Weaver KD, Yeyeodu S, Cusack JC, Baldwin AS Jr, Ewend MG (2003) Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187-196
56. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ (2003) Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 113:88-95